Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR3 | O14843 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.34 |
| ▸ | NAALAD2 | Q9Y3Q0 | 2/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4460559 | 1.00 | FFAR3 (0.35) | FFAR3TSHRGABRR1CYP1A2FOLH1 | |
| SCHEMBL2820638 | 1.00 | FFAR3 (0.35) | FFAR3TSHRGABRR1CYP1A2FOLH1 | |
| SCHEMBL3515517 | 0.92 | ALDH1A1 (0.32) | FFAR3TSHRGABRR1CYP1A2FOLH1 | |
| SCHEMBL3515511 | 0.92 | ALDH1A1 (0.32) | FFAR3TSHRGABRR1CYP1A2FOLH1 | |
| Ammonia Solution, Strong SCHEMBL6313571 | 0.85 | FOLH1 (0.30) | GABRR1CYP1A2FOLH1NAALAD2 | |
| SCHEMBL7094019 | 0.83 | GABRR1 (0.33) | GABRR1 | |
| SCHEMBL3516780 | 0.79 | — | — | |
| SCHEMBL3516784 | 0.79 | — | — | |
| SCHEMBL3860250 | 0.77 | — | — | |
| SCHEMBL188105 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0233299-B1 | OPTICAL RESIN AND PROCESS FOR PREPARING THE SAME | NIPPON OIL AND FATS COMPANY, LIMITED (JP) | 1991-03-13 | — | — | EP | claimed |
| US-20100226855-A1 | Rate-Controlled Oral Dosage Formulations | SPHERICS, INC. (US) | 2010-09-09 | — | — | US | disclosed |
| US-7608303-B2 | applying overcoating compositions that are useful as exterior clear finishes for automobiles and trucks; reactive putties; reactive cycloaliphatic norbornane derivative containing methylene amine groups react with polyisocyanate crosslinking agent to form polyurea; pot life, fast curing time | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2009-10-27 | — | — | US | disclosed |
| US-20080299204-A1 | Dosage forms for movement disorder treatment | SPHERICS, INC. (US) | 2008-12-04 | — | — | US | disclosed |
| US-20080260824-A1 | Bioadhesive Rate-Controlled Oral Dosage Formulations | SPHERICS, INC. (US) | 2008-10-23 | — | — | US | disclosed |
| US-7427647-B2 | Durable coating compositions containing aspartic amine compounds with improved potlife | E.I. DU PONT DE NEMOURS & COMPANY (US) | 2008-09-23 | — | — | US | disclosed |
| EP-1833871-B1 | DURABLE COATING COMPOSITIONS CONTAINING ASPARTIC AMINE COMPOUNDS | DU PONT (US) | 2008-08-20 | — | — | EP | disclosed |
| US-20080131492-A1 | Dosage forms for movement disorder treatment | SPHERICS, INC. (US) | 2008-06-05 | — | — | US | disclosed |
| EP-1858948-A2 | DURABLE COATING COMPOSITIONS CONTAINING ASPARTIC AMINE COMPOUNDS WITH IMPROVED POTLIFE | E.I.Du pont de nemours and company (US) | 2007-11-28 | — | — | EP | disclosed |
| EP-1833871-A1 | DURABLE COATING COMPOSITIONS CONTAINING ASPARTIC AMINE COMPOUNDS | E.I. DUPONT DE NEMOURS AND COMPANY (US) | 2007-09-19 | — | — | EP | disclosed |
| US-20060228485-A1 | Durable coating compositions containing aspartic amine compounds | E. I. DU PONT DE NEMOURS AND COMPANY | 2006-10-12 | — | — | US | disclosed |
| US-20060217565-A1 | Process for producing chromone compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2006-09-28 | — | — | US | disclosed |
| WO-2006076724-A2 | DURABLE COATING COMPOSITIONS CONTAINING ASPARTIC AMINE COMPOUNDS WITH IMPROVED POTLIFE | E.I. DUPONT DE NEMOURS AND COMPANY (US) | 2006-07-20 | — | — | WO | disclosed |
| US-20060155055-A1 | Durable coating compositions containing aspartic amine compounds with improved potlife | E. I. DU PONT DE NEMOURS AND COMPANY | 2006-07-13 | — | — | US | disclosed |
| US-20060141161-A1 | Durable coating compositions containing aspartic amine compounds | AXALTA COATING SYSTEMS IP CO. LLC (FORMERLY KNOWN AS U.S. COATINGS IP CO. LLC) | 2006-06-29 | — | — | US | disclosed |
| WO-2006066030-A1 | DURABLE COATING COMPOSITIONS CONTAINING ASPARTIC AMINE COMPOUNDS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2006-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080260824-A1 | Bioadhesive Rate-Controlled Oral Dosage Formulations | SORD, FHIT, ABCB1 | FFAR3 3140/4885TSHR 3813/4885GABRR1 656/4885 |
| US-20080131492-A1 | Dosage forms for movement disorder treatment | PARK7, SNCA, HTT | FFAR3 3986/4885TSHR 2734/4885GABRR1 231/4885 |
| US-20100226855-A1 | Rate-Controlled Oral Dosage Formulations | ABCB1, SLC47A2, CYP2D6 | FFAR3 824/4885TSHR 2855/4885GABRR1 2102/4885 |
| US-20060217565-A1 | Process for producing chromone compound | ENY2, CDY1; CDY1B, CDYL | FFAR3 559/4885TSHR 1710/4885GABRR1 4542/4885 |
| US-20080299204-A1 | Dosage forms for movement disorder treatment | PARK7, SNCA, HTT | FFAR3 3986/4885TSHR 2734/4885GABRR1 231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.